TNFRSF11B and prostate carcinoma: Interestingly, prostate cancer bone metastases also have a lytic component underlying their osteoblastic phenotype, with RANK/RANKL/OPG playing an important role [86]; actually, denosumab and bisphosphonates have been positively used also to reduce SREs in prostate cancer [86, 99].